09:12 AM EDT, 09/24/2025 (MT Newswires) -- Health care stocks were steady pre-bell Wednesday, with the Health Care Select Sector SPDR Fund ( XLV ) a slight 0.1% higher and the iShares Biotechnology ETF (IBB) inactive.

Acadia Pharmaceuticals ( ACAD ) stock was down more than 11% after the company said its ACP-101, or intranasal carbetocin, therapy candidate for patients with hyperphagia in Prader-Willi syndrome did not meet its primary efficacy endpoint in a phase 3 trial.

Soleno Therapeutics ( SLNO ) shares were up more than 13% after a rival therapy from Acadia Pharmaceuticals ( ACAD ) failed to meet its primary endpoint in a phase 3 trial.

UniQure ( QURE ) stock was up more than 153% after the company said its phase 1/2 study in Huntington's disease met its primary endpoint, with high-dose AMT-130 showing statistically significant 75% slowing of disease at 36 months as measured by the composite Unified Huntington's Disease Rating Scale.